Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A

Trial Profile

Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2017

At a glance

  • Drugs Damoctocog alfa pegol (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 13 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Oct 2017 Planned End Date changed from 10 Nov 2017 to 15 Dec 2017.
    • 11 Oct 2017 Planned primary completion date changed from 27 Oct 2017 to 30 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top